ANI Pharmaceuticals (ANIP) rare disease head sells 3,162 shares

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported an open-market sale of 3,162 shares of Common Stock. The shares were sold on March 13, 2026 at a weighted average price of $71.64 per share, in multiple trades ranging from $70.27 to $72.62.

The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following this sale, Mutz directly holds 91,309 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary 10b5-1

Net Seller: 3,162 shares ($226,526)

Net Sell 1 txn

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Sold 3,162 shs ($227K)

Type	Security	Shares	Price	Value
Sale	Common Stock	3,162	$71.64	$227K

Holdings After Transaction: Common Stock — 91,309 shares (Direct)

Footnotes (1)

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		S(1)		3,162	D	$71.64(2)	91,309	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

2. The shares were sold in multiple trades at prices ranging from $70.27 to $72.62. The price reported above reflects the weighted average sales price.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Christopher Mutz?

ANI Pharmaceuticals reported that executive Christopher Mutz sold 3,162 shares of Common Stock in an open-market transaction. The sale occurred on March 13, 2026 and was executed at a weighted average price of $71.64 per share across multiple trades within a disclosed price range.

At what prices did Christopher Mutz sell ANI Pharmaceuticals (ANIP) shares?

Christopher Mutz sold 3,162 ANI Pharmaceuticals shares at a weighted average price of $71.64. According to the filing, the shares were sold in multiple trades at prices ranging from $70.27 to $72.62, reflecting normal market execution rather than a single block trade.

How many ANI Pharmaceuticals (ANIP) shares does Christopher Mutz hold after the sale?

After the reported sale, Christopher Mutz directly holds 91,309 shares of ANI Pharmaceuticals Common Stock. This post-transaction balance is disclosed in the Form 4 and shows his remaining direct equity stake in the company following the 3,162-share open-market disposition.

Was the ANI Pharmaceuticals (ANIP) insider sale by Christopher Mutz under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Christopher Mutz on June 16, 2025. Such pre-arranged plans automate trading and are designed to reduce the influence of nonpublic information on transaction timing decisions.

What role does Christopher Mutz hold at ANI Pharmaceuticals (ANIP)?

Christopher Mutz is identified as an officer of ANI Pharmaceuticals, serving as Head of Rare Disease. His Form 4 filing reflects insider transactions in that capacity, detailing his open-market sale of common shares and his remaining direct ownership position after the transaction.